• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Whistleblower lawsuit costs Genzyme $22M

Whistleblower lawsuit costs Genzyme $22M

January 3, 2014 By Arezu Sarvestani

Whistleblower lawsuit costs Genzyme $22M

Massachusetts-based Genzyme Corp., a subsidiary of Sanofi (NYSE:SNY), agreed to pay $22.3 million to settle a whistleblower lawsuit accusing the company of off-label marketing of its Seprafilm surgical product.

Seprafilm protects organs and muscles following surgery, forming a barrier that prevents them from attaching to one another during healing.

The product has had FDA approval since 1996 for use during open surgeries, but whistleblowers claimed that Genzyme marketed the product for use during laparoscopic surgery. Genzyme sales reps allegedly encouraged doctors to mix the product into liquid form and to inject it into the body.

The company told reporters that it has taken measures to cooperate with federal investigations and to put a stop to all off-label marketing, according to the Tampa Bay Times.

The settlement comes amid tough times for Genzyme, which at the end of 2013 revealed that the FDA had struck down the company’s bid to win approval for its Lemtrada multiple sclerosis therapy, citing concerns about the product’s safety and the clinical trials used to support approval. Genzyme has said it plans to appeal the FDA’s ruling.

Filed Under: Legal News, News Well, Surgical Tagged With: Genzyme Corp., Sanofi-Aventis, Whistleblower (qui tam) lawsuit

More recent news

  • Neuronetics names Steven Pfanstiel chief financial officer
  • Medtronic to distribute Future Medical’s peripheral guidewires
  • AtriCure completes enrollment in stroke prevention trial
  • GT Medical raises $53M to support brain tumor treatment
  • Imperative Care, Proximie partner to develop surgical robot to treat stroke

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy